Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 4:05PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that George Lasezkay, Pharm.D., J.D.,
President and Chief Executive Officer and Thomas A. Ciulla, M.D.,
MBA, Chief Medical Officer and Chief Development Officer will
present a company overview at the Virtual H.C. Wainwright 22nd
Annual Global Investment Conference on September 16, 2020 at 11:30
a.m. ET.
A link to the live and archived webcast may be
accessed on the Clearside website under the Investors section:
Events and Presentations. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company
dedicated to developing and delivering treatments that restore and
preserve vision for people with serious back of the eye diseases.
Clearside’s proprietary SCS Microinjector® targets the
suprachoroidal space (SCS®) and offers unique access to the macula,
retina and choroid where sight-threatening disease often occurs.
The Company’s SCS injection platform is an inherently flexible,
in-office, non-surgical procedure, intended to provide targeted
delivery to the site of disease and to work with both established
and new formulations of medications, as well as future therapeutic
innovations such as gene therapy. For more information, please
visit www.clearsidebio.com.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024